AnaptysBio, Inc. ANAB
Set alert
47.80 USD +0.89 +1.89%
As of Nov 3, 11:51 AM ET
47.36 Day range 48.35
20.18 52-week range 72.36
- YTD
- +47.88%
- 1 year
- +98.90%
- Open
- 47.36
- Prev close
- 46.91
- Mkt cap
- 1.43B
- Vol
- 50.17K
- Avg vol
- 484.03K
- EPS
- -0.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 47.36
- High
- 48.35
- Forward P/E
- 10.34
- Beta
- 0.37
- Short ratio
- 9.41
- Inst. own
- 105.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 51.76
- 200-d avg
- 50.40
- 1y target
- 87.25
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 87.25 +82.6% upside
Now 47.80
- Target (low)
- 60.00
- Target (mean)
- 87.25
- Target (high)
- 140.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy3
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.53088 | 0.00 – 1.29 | 0.52 | +2.1% | 33.46M | -56.2% | 3 |
| Next quarter | 1.06 | 0.10 – 2.01 | 1.58 | -32.7% | 52.38M | -51.6% | 3 |
| Current year | 4.20 | 2.49 – 7.06 | -0.46 | +1012.5% | 101.12M | -56.9% | 4 |
| Next year | 4.54 | 2.42 – 8.77 | 4.20 | +8.1% | 171.31M | +69.4% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Aug 25, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 13, 2026 | UBS | Maintained | Buy | Buy |
| May 13, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 4, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Apr 28, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Apr 22, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 21, 2026 | UBS | Maintained | Buy | Buy |
| Mar 31, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 30, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 17, 2026 | UBS | Maintained | Buy | Buy |
| Mar 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 9, 2026 | Truist Securities | Maintained | Hold | Hold |
| Mar 5, 2026 | Stifel | Maintained | Buy | Buy |
| Mar 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 20, 2026 | Barclays | Maintained | Overweight | Overweight |
| Dec 17, 2025 | Barclays | Maintained | Overweight | Overweight |
| Dec 11, 2025 | Stifel | Maintained | Buy | Buy |
| Nov 24, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 24, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 11, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 10, 2025 | Truist Securities | Maintained | Hold | Hold |
| Nov 5, 2025 | Guggenheim | Maintained | Buy | Buy |
| Nov 5, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 29, 2025 | Stifel | Maintained | Buy | Buy |